GLP-1 side effects follow the dose schedule, not the calendar
Gastrointestinal effects cluster around each dose increase. In STEP-1, nausea affected roughly 44% against about 18% on placebo, and about 7% discontinued.
Reports concentrate in the days after each step up rather than spreading evenly. A person can be four months in, feel settled, step up and have a difficult week — that is the pattern the titration schedule anticipates.
In STEP-1, nausea affected roughly 44% of participants against about 18% on placebo, and about 7% discontinued for an adverse event against about 3%.
The commercial angle: approved labelling permits staying longer at a tolerated dose, and a prepaid multi-month plan commits a patient through exactly the window where discontinuation concentrates. Ask what is refundable before prepaying.
Week-by-week detail: side effects by week.
Filed by the Peptides Editorial research desk. Corrections: the corrections log.